The Ambient Light Multiple Myeloma Study

The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. While receiving these light treatments, participants' sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels and symptoms will be assessed over a 2-mo

Trial Details

NCT ID
NCT05737732
Phase
NA
Sponsor
Icahn School of Medicine at Mount Sinai
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Circadian Effective Lighting
  • Circadian Ineffective Lightning (CIL)
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Multiple Myeloma diagnosis
  • Scheduled to undergo their first Autologous Stem Cell Transplant procedure.
  • 21years or older
  • Able to provide informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →